Latest News & Features
Americas
The smartphone wars may have slowed down but many smaller high-tech companies continue to assert their IP rights against competitors, as the fitness tracker battle shows. Fabio Marino and Luc Dahlin of McDermott Will & Emery report. 22 December 2015
Big Pharma
India-based life sciences company Glenmark Pharmaceuticals has confirmed that it has ended its patent dispute with Forest Laboratories. 21 December 2015
Big Pharma
The US Court of Appeals for the Federal Circuit’s affirmation of the Patent Trial and Appeal Board’s decision to invalidate a Merck patent used to reduce homocysteine in the human body faced criticism from a dissenting judge, who claimed the court showed too much deference to the body’s decision. 18 December 2015
Generics
Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product. 17 December 2015
Big Pharma
The complex rules around the filing of divisional applications relating to priority of patent claims are designed to maintain the integrity of the first-to-file system, as Ashley Roughton of Nabarro explains. 17 December 2015
Americas
Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass. 16 December 2015
Americas
Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled. 15 December 2015
Americas
Pharmaceutical company Gilead Sciences has settled its patent dispute with Indian-based rival Natco Pharma over an attempt to market a generic version of its Tamiflu product. 14 December 2015
Americas
The Patent Trial and Appeal Board has rejected the Coalition for Affordable Drugs' attempt to invalidate a patent covering Pozen’s Vimovo (naproxen and esomeprazole magnesium) drug. 11 December 2015
Big Pharma
Teva has been handed a victory after a patent covering its multiple sclerosis drug Copaxone (glatiramer acetate) was declared valid until 2030. 10 December 2015